Presentation at the FDA’s Public Meeting on the Reauthorization of PDUFA
View complete testimony as PDF
In its presentation at the Food and Drug Administration’s (FDA’s) kickoff public meeting to discuss proposed recommendations for the reauthorization of the Prescription Drug User Fee Act (PDUFA) for fiscal years 2023 through 2027, Public Citizen expressed its long-standing strong opposition to the FDA’s user fee programs and offered several recommendations for strengthening the agency’s oversight of prescription drugs to better protect patients from unsafe or ineffective products.
See Public Citizen’s other work regarding the drug approval process.